0.25 mg 2 mL Budesonide Inhalation Suspension Carton.jpg (0.25 mg 2 mL Budesonide Inhalation Suspension Carton.jpg)
Budesonide Suspension
Product Images NDC 60687-889
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Budesonide (NDC 60687-889). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
0.25 mg 2 mL Budesonide Inhalation Suspension Foil Pouch.jpg (0.25 mg 2 mL Budesonide Inhalation Suspension Foil Pouch.jpg)
This text provides information about a medication called Budesonide Inhalation Suspension, delivered in single-dose ampules for inhalation use only. The suspension contains specified ingredients and must be used with a nebulizer as directed by a physician. The text also gives storage instructions, dosage information, and safety warnings. The medication is distributed by American Health Packaging from Columbus, Ohio.*
Spl-budesonide-fig-1 (Spl Budesonide Fig 1)
This text shows the results of a 12-Week Trial in Pediatric Patients who were not on Inhaled Corticosteroid Therapy prior to the study entry, focusing on the change in nighttime asthma symptoms from baseline. Different dosage groups (0.25 mg, 0.5 mg, and 1.0 mg once daily) were compared with a placebo. The mean changes from baseline are presented for each group over the course of the study period. The p-values indicate the statistical significance of the differences between each dosage group and the placebo regarding nighttime asthma symptoms.*
Spl-budesonide-fig-2 (Spl Budesonide Fig 2)
This is a summary of a 12-week trial conducted on pediatric patients who were previously on inhaled corticosteroid therapy. The trial evaluated the change in nighttime asthma symptoms from baseline over the course of the study, comparing the effects of a placebo, 0.25 mg twice daily, and 0.5 mg twice daily. The mean change from baseline was calculated for each treatment group at different intervals throughout the 12 weeks. The results indicate statistically significant p-values for the 0.25 mg and 0.5 mg doses compared to the placebo.*
Spl-budesonide-fig-3 (Spl Budesonide Fig 3)
This is a figure showing the results of a 12-week trial in pediatric patients with nighttime asthma who were either maintained on bronchodilators alone or inhaled corticosteroid therapy prior to the study entry. The figure displays the change from baseline in nighttime asthma symptoms over the 12-week period. Different treatment groups are represented by different dosages of medication: 0.25mg once daily, 0.25mg twice daily, 0.5mg twice daily, and 1.0mg once daily. P-values for each dosage group are provided for statistical evaluation.*
Spl-budesonide-fig-5 (Spl Budesonide Fig 5)
Spl-budesonide-fig-6 (Spl Budesonide Fig 6)
Spl-budesonide-fig-7 (Spl Budesonide Fig 7)
Spl-budesonide-str (Spl Budesonide Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
